Repare Therapeutics Inc. (RPTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration agreements | 250 | - | - | |
| Restructuring | 3,384 | 3,265 | 1,527 | |
| Research and development, net of tax credits | 14,283 | 20,270 | 28,401 | |
| General and administrative | 6,029 | 7,652 | 6,444 | |
| Total operating expenses | 23,696 | 31,187 | 36,372 | |
| Gain on sale of technology and other assets | 5,666 | - | - | |
| Loss from operations | -17,780 | -31,187 | -36,372 | |
| Other expense, net | 18 | 22 | 42 | |
| Interest income | 1,236 | 1,538 | 2,512 | |
| Realized and unrealized gain on foreign exchange | 66 | -2 | -19 | |
| Total other income, net | 1,284 | 1,514 | 2,451 | |
| Loss before income taxes | -16,496 | -29,673 | -33,921 | |
| Income tax expense | 248 | 370 | 485 | |
| Net loss | -16,744 | -30,043 | -34,406 | |
| Unrealized loss on available-for-sale marketable securities | -17 | -45 | 274 | |
| Unrealized loss on available-for-sale marketable securities | - | - | - | |
| Total other comprehensive loss | -17 | -45 | 274 | |
| Comprehensive loss | -16,761 | -30,088 | -34,132 | |
| Earnings per share, basic | -0.39 | -0.71 | -0.81 | |
| Earnings per share, diluted | -0.39 | -0.71 | -0.81 | |
| Weighted average number of shares outstanding, basic | 42,921,936 | 42,591,730 | 42,452,617 | |
| Weighted average number of shares outstanding, diluted | 42,921,936 | 42,591,730 | 42,452,617 | |